Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance

Valerie Barbier, Johanna Erbani (), Corrine Fiveash, Julie M. Davies, Joshua Tay, Michael R. Tallack, Jessica Lowe, John L. Magnani, Diwakar R. Pattabiraman, Andrew C. Perkins, Jessica Lisle, John E. J. Rasko, Jean-Pierre Levesque and Ingrid G. Winkler ()
Additional contact information
Valerie Barbier: Translational Research Institute
Johanna Erbani: Translational Research Institute
Corrine Fiveash: Translational Research Institute
Julie M. Davies: Translational Research Institute
Joshua Tay: Translational Research Institute
Michael R. Tallack: Translational Research Institute
Jessica Lowe: Translational Research Institute
John L. Magnani: GlycoMimetics Inc.
Diwakar R. Pattabiraman: Translational Research Institute
Andrew C. Perkins: Translational Research Institute
Jessica Lisle: Translational Research Institute
John E. J. Rasko: Centenary Institute, University of Sydney
Jean-Pierre Levesque: Translational Research Institute
Ingrid G. Winkler: Translational Research Institute

Nature Communications, 2020, vol. 11, issue 1, 1-15

Abstract: Abstract The endothelial cell adhesion molecule E-selectin is a key component of the bone marrow hematopoietic stem cell (HSC) vascular niche regulating balance between HSC self-renewal and commitment. We now report in contrast, E-selectin directly triggers signaling pathways that promote malignant cell survival and regeneration. Using acute myeloid leukemia (AML) mouse models, we show AML blasts release inflammatory mediators that upregulate endothelial niche E-selectin expression. Alterations in cell-surface glycosylation associated with oncogenesis enhances AML blast binding to E-selectin and enable promotion of pro-survival signaling through AKT/NF-κB pathways. In vivo AML blasts with highest E-selectin binding potential are 12-fold more likely to survive chemotherapy and main contributors to disease relapse. Absence (in Sele−/− hosts) or therapeutic blockade of E-selectin using small molecule mimetic GMI-1271/Uproleselan effectively inhibits this niche-mediated pro-survival signaling, dampens AML blast regeneration, and strongly synergizes with chemotherapy, doubling the duration of mouse survival over chemotherapy alone, whilst protecting endogenous HSC.

Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-020-15817-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-15817-5

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-15817-5

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().